UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

~~FORM~~Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~November~~June ~~2025~~2026

Commission File Number: 333-269315

~~CORDYCEPS~~Cordyceps Sunshine ~~SUNSHINE~~Biotech ~~BIOTECH~~Holdings ~~HOLDINGS CO~~Co., ~~LTD~~Ltd.

(Translation of registrant’s name into English)

6th Fl., No. 15, Lane 548, Ruiguang Road, ~~Neihu District, Taipei City, Taiwan~~

Neihu District, Taipei City, Taiwan

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:.

Form 20-F ☒ Form 40-F ☐

~~Changes~~Entry ininto ~~Company’s~~Material ~~Certifying~~Definitive ~~Accountant.~~Agreements

Cordyceps Sunshine Biotech Holdings Co., Ltd. (1“RAJAF” or the “Company”) ~~Previous~~announces ~~Independent~~that ~~Registered~~it ~~Public~~has ~~Accounting~~entered into a Cooperation and Development Agreement (the “Agreement”) ~~Firm~~with Pet Sunshine Biological Research Co., Ltd.

~~(i)~~The ~~Effective~~Agreement onestablishes ~~November~~a ~~10,~~framework ~~2025,~~for ~~Cordyceps~~cooperation ~~Sunshine~~relating ~~Biotech~~to ~~Holdings~~the future ~~Co.~~development, ~~Ltd.~~commercialization, ~~(the~~intellectual ~~“Company”)~~property ~~terminated~~expansion, ~~KCCW~~manufacturing ~~Accountancy~~collaboration ~~Corp.~~and aspotential ~~the~~capital ~~Company’s~~markets ~~independent~~integration associated ~~registered~~with ~~public accounting firm~~TFA-01.

TFA-01 (iiAntcin A) ~~The~~is ~~reports~~being ofdeveloped ~~KCCW~~as ~~Accountancy~~a ~~Corp.~~next-generation onnon-steroid anti-inflammatory ~~consolidated~~Platform ~~balance~~Molecule ~~sheets of the Company~~ for ~~the~~animal ~~fiscal~~drug year ended December 31, 2024 and 2023 and the consolidated statements of operations and comprehensive loss, consolidated statements of changes in shareholders’ equity (deficit), and consolidated statements of cash flows for the fiscal years ended December 31, 2024, and 2023, did not contain an adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principlesapplications.

~~(iii)~~ The ~~decision~~Agreement tois ~~change~~intended ~~the~~to ~~independent~~establish ~~registered~~a ~~public~~foundation ~~accounting~~for ~~firm~~cooperation, commercialization ~~was~~opportunities ~~approved~~and bycapital ~~the~~markets ~~Board~~initiatives ofrelating ~~Directors~~to ~~of the Company~~TFA-01.

(iv) During the Company’s most recent fiscal year ended December 31, 2024 and through November 10, 2025, the date of dismissal, (a) there were no disagreements with KCCW Accountancy Corp. on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of KCCW Accountancy Corp., would have caused it to make reference thereto in its reports on the financial statements for such year and (b) there were no “reportable events” as described in Item 304(a)(1)(v) of Regulation SForward-K.Looking Statements

~~(v)~~Matters ~~The~~discussed ~~Company~~in ~~provided~~this ~~KCCW~~report ~~Accountancy~~may ~~Corp~~constitute forward-looking statements. Forward-looking ~~with~~statements ainclude ~~copy~~statements ofconcerning ~~this~~plans, ~~Current~~objectives, ~~Report~~goals, ~~and~~strategies, ~~has~~future ~~requested~~events ~~that~~or itperformance, ~~furnish~~and ~~the~~underlying assumptions ~~Company~~and ~~with~~other astatements, ~~letter~~other ~~addressed~~than tostatements ~~the~~of Uhistorical facts.S. ~~Securities~~The ~~and~~words ~~Exchange~~“believe,” ~~Commission~~“anticipate,” “intends,” ~~stating~~“estimate,” ~~whether~~“potential,” it“may,” ~~agrees~~“should,” ~~with~~“expect”, “pending” ~~the~~and ~~above~~similar expressions identify forward-looking statements. AThe ~~copy~~forward-looking ofstatements ~~such~~in ~~letter~~this isreport ~~attached~~are asbased upon ~~Exhibit~~various 16assumptions.1 Although we believe that these assumptions were reasonable when made, because these assumptions are inherently subject to ~~this~~significant ~~Report~~uncertainties ofand ~~Foreign~~contingencies ~~Private~~which ~~Issuer~~are ondifficult ~~Form~~or ~~6-K~~impossible to predict and are beyond our control, we cannot assure you that we will achieve or accomplish these expectations.

(2) New Independent Registered Public Accounting Firm

On November 15, 2025, the Board of Directors of the Company approved and ratified the appointment of YCM CPA INC. as its new independent registered public accounting firm to audit the Company’s financial statements, effective November 15, 2025. During the two most recent fiscal years ended December 31, 2024 and 2023 and any subsequent interim periods through the date hereof prior to the engagement of YCM CPA INC., neither the Company, nor someone on its behalf, has consulted YCM CPA INC. regarding:

(i) either: the application of accounting principles to a specified transaction, either completed or proposed; or the type of audit opinion that might be rendered on the Company’s consolidated financial statements, and either a written report was provided to the Company or oral advice was provided that the new independent registered public accounting firm concluded was an important factor considered by the Company in reaching a decision as to the accounting, auditing or financial reporting issue; or

(ii) any matter that was either the subject of a disagreement as defined in paragraph 304(a)(1)(iv) of Regulation S-K or a reportable event as described in paragraph 304(a)(1)(v) of Regulation S-K.

Exhibit Index

Exhibit No.		Description
16.1		Letter from KCCW Accountancy Corp. addressed to the U.S. Securities and Exchange Commission
99.1		Cooperation and Development Agreement for the Antcin A Platform

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CORDYCEPS SUNSHINE BIOTECH HOLDINGS CO., LTD.
Date: June 25, 2026	Cordyceps Sunshine Biotech Holdings Co., Ltd.
Date: November 25, 2025	By:	/s/ Szu Hao Huang
	By:	/s/ Szu Hao Huang
	Name:	Szu Hao Huang
	Title:	Director, Chief Executive Officer, Chief Financial Officer~~, Director~~

Filing Compare · Cordyceps Sunshine Biotech Holdings Co., Ltd.